| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Comparative Effectiveness Study of PTSD Treatments Among Sexual and Gender Minority Populations | N/A | Stanford University | <1 mi |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Phase 3 | Cybin IRL Limited | <1 mi |
| Neural Mechanisms of Meditation Training in Healthy and Depressed Adolescents: An MRI Connectome Study PART 2 | N/A | University of California, San Francisco | <1 mi |
| Treating Major Depression With Yoga Mono-therapy | N/A | University of California, San Francisco | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Probiotic Administration for Adolescent Depression | Early 1 | University of California, San Francisco | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| Closed-Loop Deep Brain Stimulation for Major Depression | N/A | Andrew Krystal | <1 mi |
| Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression | N/A | San Francisco Veterans Affairs Medical Center | <1 mi |
| Better Sleep Study | N/A | University of California, San Francisco | <1 mi |
| Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression | N/A | Andrew Krystal | <1 mi |
| Reward Processing and Depressive Subtypes: Identifying Neural Biotypes | — | San Francisco Veterans Affairs Medical Center | <1 mi |
| Near Infrared Spectroscopy (NIRS) for Assessment of Depression | N/A | University of California, San Francisco | <1 mi |
| Biomarkers of Depression and Treatment Response | N/A | University of California, San Francisco | <1 mi |
| Model-based Electrical Brain Stimulation | N/A | University of Southern California | <1 mi |
| Building Resilience for Surgical Recovery | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project | — | University of Southern California | <1 mi |
| SUpport From PEeRs to Expand Access Study - Community | N/A | University of California, Berkeley | <1 mi |
| Ketamine for Veterans With Parkinson's Disease | Phase 2 | VA Office of Research and Development | <1 mi |
| Psilocybin Therapy for Depression in Parkinson's Disease | Phase 2 | Joshua Woolley, MD, PhD | <1 mi |
| Kintsugi Voice Device Pivotal Study | — | Kintsugi Mindful Wellness, Inc. | 10 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | 14 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | 18 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | 18 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | 18 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | 21 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | 21 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | 21 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | 21 mi |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 21 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | 21 mi |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Phase 3 | Axsome Therapeutics, Inc. | 21 mi |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Phase 2 | Autobahn Therapeutics, Inc. | 21 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 21 mi |
| Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder | N/A | Stanford University | 28 mi |
| rTMS for Military TBI-related Depression | N/A | Henry M. Jackson Foundation for the Advancement of Military Medicine | 28 mi |
| ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression | Phase 2 | Stanford University | 28 mi |
| Sensory Synchronized Imaging and Neuromodulation | N/A | VA Office of Research and Development | 28 mi |
| Sleep Mechanisms Of Regulating Emotions | N/A | Stanford University | 28 mi |
| Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression | N/A | Stanford University | 28 mi |
| Biomarker-guided rTMS for Treatment Resistant Depression | Phase 3 | Weill Medical College of Cornell University | 28 mi |
| fMRI Neurofeedback With Matter Neuroscience App | N/A | Stanford University | 28 mi |
| Behavioral and Neuronal Correlates of Human Mood States | N/A | Stanford University | 28 mi |
| Optimizing Brain Excitability in Depression | N/A | Stanford University | 28 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | 28 mi |
| Virtual Reality-Enhanced Behavioral Activation for Older Adults With Depression | N/A | Stanford University | 28 mi |
| Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans | N/A | Stanford University | 28 mi |
| The Effect of Hyperoxia on Ventilation During Recovery From General Anesthesia | N/A | Stanford University | 28 mi |
| Closed-loop Optimized rTMS for Depression | N/A | Stanford University | 28 mi |
| The BEAR Program for Women With Trauma Who Have Suicidal Thoughts | N/A | Stanford University | 28 mi |
| Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements | — | Kernel | 35 mi |
| Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness | Phase 2 | Brigham and Women's Hospital | 35 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | 42 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | 42 mi |
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 42 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | 49 mi |